Alabama Healthcare Simulation Alliance

Buprenorphine for the Treatment of Opioid Use Disorder: A Patient-Centered and Harm Reductionist Approach

CE Information
1.0 CE credit (1.0 pharmacology)
Completion Time
1 hour
Ready to start this activity?
Already registered? Please log in to see your registration information.
You will be redirected to the association site for Association of Psychiatric Mental Health Nurse Practitioners to complete your registration.

Overview

Specialties
Psychiatric / Mental Health
Subspecialties
Other and Primary Care
Clinical Topics
Pharmacology

This course will provide an overview of pharmacotherapy for opioid use disorder, with a focus on buprenorphine. Current epidemiology related to opioid use disorder will be discussed, with clinical pearls provided related to best practices in pharmacotherapy. Utilization of a patient-centered and harm reductionist approach will also be covered, with an introduction to motivational interviewing.

  • Verbalize current epidemiology of opioid use disorders
  • Discuss best practices related to pharmacotherapy for opioid use disorder
  • Utilize motivational interviewing techniques

Learning Objectives

  • Verbalize current epidemiology of opioid use disorders
  • Discuss best practices related to pharmacotherapy for opioid use disorder
  • Utilize motivational interviewing techniques

Speakers

Brayden Kameg
Brayden Kameg DNP, PMHNP-BC, CARN-AP

Assistant Professor of Nursing at the University of Pittsburgh

Dr. Brayden Kameg currently serves as an Assistant Professor of Nursing in the Department of Health and Community Systems, where she coordinates the psychiatric-mental health nurse practitioner (PMHNP) program. She currently teaches across undergraduate and graduate programs. Her primary teaching responsibilities include family therapy, psychopharmacology, and psychiatric management in primary care. Additionally, she serves as the clinical course coordinator for the undergraduate psychiatric-mental health nursing course. Dr. Kameg’s academic interests include integrating substance use and mental-health-related competencies across undergraduate and graduate programs. She has received extramural funding through the Health Resources and Services Administration (HRSA), Substance Abuse and Mental Health Services Administration (SAMHSA), and the National Institute on Drug Abuse. This funding has supported her work which seeks to improve the ability of both nurses and nurse practitioners to meet the mental and behavioral healthcare needs of the populations that they serve.

CE Information

This activity offers 1.0 CE credit (1.0 pharmacology) to attendees.

Accredited by Provider approved by the California Board of Registered Nursing, Provider # 17810.

This course will provide an overview of pharmacotherapy for opioid use disorder, with a focus on buprenorphine. Current epidemiology related to opioid use disorder will be discussed, with clinical pearls provided related to best practices in pharmacotherapy. Utilization of a patient-centered and harm reductionist approach will also be covered, with an introduction to motivational interviewing.

  • Verbalize current epidemiology of opioid use disorders
  • Discuss best practices related to pharmacotherapy for opioid use disorder
  • Utilize motivational interviewing techniques

Disclosures

None

Activity Content

Key:
Locked
Next
Complete
Failed
0% Complete
Activity Attachments

Registration to this activity includes access to the following supporting materials.

  • Slides (Size: 5.42 MB)
Presentation
Duration: about 1 hour | Quality: HD
Course Evaluation
6 questions
Post-Test
3 questions | 2 correct test question required to pass
Certificate
Access your certificate

Register For This Activity

Non-Member Registration

This course will provide an overview of pharmacotherapy for opioid use disorder, with a focus on buprenorphine. Current epidemiology related to opioid use disorder will be discussed, with clinical pearls provided related to best practices in pharmacotherapy. Utilization of a patient-centered and harm reductionist approach will also be covered, with an introduction to motivational interviewing.

$19.00

APMHNP Members

This course will provide an overview of pharmacotherapy for opioid use disorder, with a focus on buprenorphine. Current epidemiology related to opioid use disorder will be discussed, with clinical pearls provided related to best practices in pharmacotherapy. Utilization of a patient-centered and harm reductionist approach will also be covered, with an introduction to motivational interviewing.

Free